TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$119.15 USD
+4.86 (4.25%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $118.87 -0.28 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TMDX 119.15 +4.86(4.25%)
Will TMDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMDX
Why TransMedics (TMDX) is a Top Growth Stock for the Long-Term
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is TransMedics (TMDX) Down 1.9% Since Last Earnings Report?
Here's Why TransMedics (TMDX) is a Strong Momentum Stock
Here's Why TransMedics (TMDX) is a Strong Growth Stock
Other News for TMDX
TransMedics Group (TMDX): Evercore ISI Initiates Coverage with 'Outperform' Rating | TMDX Stock News
Apple initiated, Hershey upgraded: Wall Street’s top analyst calls
Apple initiated, Hershey upgraded: Wall Street's top analyst calls
TransMedics Group (TMDX) Has a New Rating from Roth MKM
Crossed Above 20 Day Moving Average appears for TMDX after 0.24% move